|
|
|
|
|
|||||||
|
Session 49
Poster Session
Vaccine Related Studies 4:30-6:30 pm 4E-F |
to view the poster for an abstract.| 294-W. | HIV Seropositivity among Uninfected HIV Vaccine Recipients M-L. Ackers*1, B. Parekh1, T. G. Evans2,3, P. Berman4, S. Phillips1, M. Allen5, and J. S. McDougal1 1CDC, Atlanta, GA; 2Univ. of Rochester, NY; 3AIDS Vaccine Evaluation Group (AVEG); 4VaxGen, Inc., Brisbane, CA; and 5NIH, Bethesda, MD
| ||
| 295-W. | Contamination of Fetal Bovine Serum with Bovine Viral Diarrhea Virus: An Issue for Manufacturers of HIV-1 Vaccines L. Jagodzinski*1, J. Cooley1, S. Kelly1, T. VanCott1, and N. Michael2 1Henry M. Jackson Fndn. and 2Walter Reed Army Inst. Res. Program, Rockville, MD
| ||
| 297-W. | Vaccine Strategies for the Induction of Neutralizing Antibodies and Cellular Immune Responses against HIV-1 Subtype C Strains S. W. Barnett1, I. R. Srivastava1, J. zur Megede1, Y. Lian1, Y. Sun1, S. Hilt1, E. Kan1, T. Scriba2, S. Engelbrecht2, E. Janse van Rensburg2, G. Otten1, J. B. Ulmer1, and J. J. Donnelly1 1Chiron Corp., Emeryville, CA and 2Univ. of Stellenbosch and Tygerberg Hosp., South Africa
| ||
| 298-W. | Recombinant SV40 as a Vaccine Delivery Vehicle against HIV-1 Envelope gp120 H. McKee* and D. Strayer Jefferson Med. Coll., Philadelphia, PA
| ||
| 299-W. | Rhabdovirus-Based Vectors Expressing HIV-1 Env or Gag Induce Vigorous Cellular Responses against HIV-1 and Infect Efficiently Human Dendritic Cells J. McGettigan1, H. D. Foley1, S. Sarma1, M. Otero1, C. A. Siler1, J. Orenstein2, R. J. Pomerantz1, and M. J. Schnell*1 1Thomas Jefferson Univ., Philadelphia, PA and 2George Washington Univ. Med. Ctr., Washington, DC
| ||
| 300-W. | A Novel Chimeric Rev, Tat, and Nef Antigen as a Component of an SIV/HIV Vaccine Z. Hel*1, J. M. Johnson1 , E. Tryniszewska1, 2 , W-P. Tsai1 , R. Harrod1 , J. Fullen1 , J. Tartaglia3, and G. Franchini1 1NCI, NIH, Bethesda, MD; 2Med. Academy of Bialystok, Poland; and 3Aventis-Pasteur, Toronto, ON, Canada
| ||
| 301-W. | Evolution in Culture of Constitutively Dead, Conditionally Live HIV-1 Genomes, an Attenuated Viral Vaccine with the Regulated Replication M. Khoroshev*1, K. T. Jeang2, and S. Smith1 1New Jersey Med. Sch. and St. Michael's Med. Ctr., Newark; and 2NIAID, NIH, Bethesda, MD
| ||
| 302-W. | Comparative Analysis of Immune Response Elicited in Rabbits by the Combined Use of Recombinant Avipoxviruses, Plasmids, and Virus-Like Particles (VLPs) in Prime-Boost Vaccination Protocols A. Radaelli1, C. De Giuli Morghen*1, V. Elli1, E. Vicenti2, G. Poli2, V. Basavecchia1, and C. Zanotto1 1Univ. of Milan and 2S. Raffaele Sci. Inst., Milan, Italy
| ||
| 303-W. | Potentiation of SIV-Specific CD4+ and CD8+ T-Cell Responses by a DNA-SIV and NYVAC-SIV Prime-Boost Regimen Z. Hel1, W-P. Tsai*1, A. Thornton1, J. Nacsa1, L. Giuliani1, E. Tryniszewska1, 2, M. Poudyal1, D. Venzon1 , X. Wang3, J. Altman3 , D. I. Watkins4, W. Lu5 , A. von Gegerfelt5, B. K. Felber5, J. Tartaglia6, G. N. Pavlakis5, and G. Franchini1 1NCI, NIH, Bethesda, MD; 2Med. Academy of Bialystok, Poland; 3Emory Univ. Vaccine Ctr., Yerkes, Atlanta, GA; 4Wisconsin Regional Primate Res. Ctr., Madison; 5NCI, NIH, Frederick, MD; and 6Aventis-Pasteur, Toronto, ON, Canada
| ||
| 304-W. | Differential Epitope-Recognition by Antibodies Elicited during Immunization with the C. Buckner1, A. Gettie2, J. Blanchard2, S. Barnett3, I. Srivastava3, K. VanDorsten4, and L. Stamatatos*4 1Aaron Diamond AIDS Res. Ctr., Rockefeller Univ., New York, NY; 2Tulane Regional Primate Res. Ctr., Convington, LA; 3Chiron Corp., Emeryville, CA; and 4Seattle BioMed. Res. Inst., WA
| ||
| 305-W. | Modifications in the Cytoplasmic Domain of HIV-1 Env Allow Exposure of the Conserved Co-Receptor-Binding Site and Enhance Neutralization Sensitivity F. Baribaud*1, T. Edwards1, S. Wyss1, J. Reeves1, S. Zolla-Pazner2, J. Hoxie1, and R. W. Doms1 1Univ. of Pennsylvania, Philadelphia and 2VA Med. Ctr., New York, NY
| ||
| 306-W. | Enhanced Neutralizing Antibody Responses Induced in Rhesus Macaques by o-gp140DV2 SF162 in a Prime-Boost Regimen I. Srivastava*2, E. Kan1, Y. Sun1, L. Stamatatos2, D. Montefiori3, G. Otten1, D. O'Hagan1, M. Singh1, J. J. Donnelly1, J. Ulmer1, and S. Barnett1 1Chiron Corp., Emeryville, CA; 2Seattle BioMed. Res. Inst., WA; and 3Duke Univ. Med. Ctr., Durham, NC
| ||
| 307-W. | Effect of DC Pulsed with Oligo-Arginine Conjugated HIV Polypeptides in HLA-A2 Transgenic Mice S. K. Kundu-Raychaudhuri*1, J. Rothbard2, E. G. Engleman1, and T. C. Merigan1 1Stanford Univ. Med. Ctr., Palo Alto and 2Cellgate Inc., Sunnyvale, CA
| ||
| 308-W. | Novel HIV Immunogen: HIV Gag-Env Chimerical Protein Conjugated with Potent Immunomodulator Polyoxidonium I. Nikolaeva*1, 3, A. Chevalier1, 3, S. Korobova1, 3, G. Ignatjeva1, 3, E. Karamov2, 3, A. Nekrasov1, 3, R. Khaitov1, 3, I. Sidorovich1, and 3 1Inst. of Immunology RF Ministry of Hlth., Moscow; 2D. Ivanovsky Inst. of Virology RAMS, Moscow; and 3Moscow HIV Vaccine Trials Site, Russia
| ||
| 309-W. | Class I-Restricted Cross-Presentation of HIV-1 Vaccinal Lipopeptides in Human Dendritic Cells M. Andrieu*1, J-F. Desoutter1, E. Loing2, D. Hanau3, J-G Guillet1, and A. Hosmalin1 1ICGM, Paris; 2SEDAC-Therapeutics, Lille; and 3ETS, Strasbourg, France
| ||
| 310-W. | Generation of Th1-Type HIV-1-Specific Immune Responses to gp120-Depleted HIV-1 Immunogen in Mice with Preexistent Th2 Immune Profile: Relevance to Vaccination in Developing Countries M. Ayash-Rashkovsky1, Z. Weisman1, J. Diveley2, R. B. Moss2, G. Borkow1, and Z. Bentwich*1 1Hebrew Univ. Hadassah Med. Sch., Rehovot, Israel and 2Immune Response Corp., Carlsbad, CA
| ||
| 311-W. | A Glycoprotein-Deficient Rhabdovirus Expressing HIV-1 gp160 Mimics an HIV-1-Like Tropism and Targets Human Dendritic Cells: Indication for a Novel HIV-1 Vaccine Approach H. D. Foley1, J. McGettigan1, M. Otero1, C. A. Siler1, J. Orenstein1, R. J. Pomerantz1, and M. J. Schnell*1 1Thomas Jefferson Univ., Philadelphia, PA and 2George Washington Univ. Med. Ctr., Washington, DC
|
